Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease

Journal of the American College of Cardiology

Volumn 33, Issue 7, 1999, Pages 2030-2037

  Herrington, David M ^a   Werbel, Brian L ^a   Riley, Ward A ^a   Pusser, Benjamin E ^a   Morgan, Timothy M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; MEVINOLIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LOVASTATIN; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATION;

EID: 0032694881     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00128-X     Document Type: Article

References (62)

1. Grodstein F., Stampfer M.J., Goldhaber S.Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
2. Sullivan J.M. Estrogen replacement therapy. Am J Med. 101:1996;56S-59S.
3. Gerhard M., Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation. 92:1995;5-8.
4. Grundy S.M., Balady G.J., Criqui M.H., et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 95:1997;2329-2331.
5. Second report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 89:1994;1329-1445.
6. Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. Circulation 1995;92:2-4.
7. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
8. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
9. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 73:1994;951-952.
10. Collins P., Rosano G.M., Sarrel P.M., et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;24-30.
11. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
12. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
13. Fan L, Jariel I, Herrington DM. A spatiotemporal strategy for automated analysis of vasodilator response. Comput Cardiol 1998;25:161-4.
14. Herrington D.M., Werbel B.L., Riley W.A., Kitzman D.W., Warner J.G., Fan L. Single measurements of brachial artery diameter significantly underestimate endothelial-dependent vasomotor responses. J Am Coll Cardiol. 29:1997;44A.
15. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
16. Corretti M.C., Plotnick G.D., Vogel R.A. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol. 268:1995;H397-H404.
17. Burstein M., Samaille J. Sur un dosage rapide du cholesterol lie aux a- et aux b-lipoproteines du serum. Clin Chem Acta. 5:1960;609.
18. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Bethesda (MD): U.S. Department of Health, Manual of Laboratory Operations, 1974:75-628.
19. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
20. SAS/STAT User's Guide. 4th ed. Cary (NC): SAS Institute, 1989.
21. Milliken G.A., Johnson D.E. Analysis of Messy Data. 1984;445-450 Van Nostrand Reinhold Company, New York.
22. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1991;1196-1204.
23. Lobo R.A., Pickar J.H., Wild R.A., Walsh B., Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol. 84:1994;987-995.
24. Kim C.J., Min Y.K., Ryu W.S., Kwak J.W., Ryoo U.H. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med. 156:1996;1693-1700.
25. Milner M.H., Sinnott M.M., Cooke T.M., Kelly A., McGill T., Harrison R.F. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol. 87:1996;593-599.
26. Whitcroft S.I., Crook D., Marsh M.S., Ellerington M.C., Whitehead M.I., Stevenson J.C. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol. 84:1994;222-226.
27. Koh K.K., Mincemoyer R., Bui M.N., et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 336:1997;683-690.
28. Tonstad S., Ose L., Gorbitz C., Djoseland O., Bard J.M., Fruchart J.C. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern Med. 238:1995;39-47.
29. Davidson M.H., Testolin L.M., Maki K.C., von Duvillard S., Drennan K.B. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med. 157:1997;1186-1192.
30. Granfone A., Campos H., McNamara J.R., et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism. 41:1992;1193-1198.
31. Darling G.M., Johns M.D., McCloud P.I., Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 337:1997;595-601.
32. Gisclard V., Miller V.M., Vanhoutte P.M. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 244:1988;19-22.
33. Bell D.R., Rensberger H.J., Koritnik D.R., Koshy A. Noradrenergic vasorelaxation of porcine coronary arteries is enhanced by direct, acute exposure to 17 beta-estradiol. Gen Pharmacol. 26:1995;1289-1294.
34. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 20:1992;452-457.
35. Reis S.E. Oestrogens attenuate abnormal coronary vasoreactivity in postmenopausal women. Ann Med. 26:1994;387-388.
36. Gilligan D.M., Quyyumi A.A., Cannon R.O. III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
37. Williams J.K., Adams M.R., Klopfenstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 81:1990;1680-1687.
38. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., Cannon R.O. III. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
39. Lieberman E.H., Gerhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
40. Gerhard M., Walsh B.W., Tawakol A., et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 98:1998;1158-1163.
41. Bush D.E., Jones C.E., Bass K.M., et al. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med. 104:1998;552-558.
42. McCrohon J.A., Adams M.R., McCredie R.J., et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf). 45:1996;435-441.
43. Williams J.K., Honore E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 24:1994;1757-1761.
44. Sorensen K.E., Dorup I., Hermann A.P., Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 97:1998;1234-1238.
45. Bradford R.H., Downton M., Chremos A.N., et al. Efficacy and tolerability of lovastatin in 3,390 women with moderate hypercholesterolemia. Ann Intern Med. 118:1993;850-855.
46. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
47. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
48. Vogel R.A., Corretti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol. 77:1996;36-49.
49. Espeland M.A., Applegate W., Furberg C.D., Lefkowitz D., Rice L., Hunninghake D. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Asymptomatic Carotid Artery Progression Study. Am J Epidemiol. 142:1995;1011-1019.
50. Stensvold I., Tverdal A., Urdal P., Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 307:1993;1318-1322.
51. Campos H., Sacks F.M., Walsh B.W., Schiff I., O'Hanesian M.A., Krauss R.M. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism. 42:1993;1153-1158.
52. Liao L., Granger D.N. Modulation of oxidized low-density lipoprotein-induced microvascular dysfunction by nitric oxide. Am J Physiol. 268:1995;H1643-H1650.
53. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 320:1986;454-456.
54. Seccombe J.F., Pearson P.J., Schaff H.V. Oxygen radical-mediated vascular injury selectively inhibits receptor-dependent release of nitric oxide from canine coronary arteries. Thorac Cardiovasc Surg. 107:1994;505-509.
55. Rosano G.M., Sarrel P.M., Poole-Wilson P.A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 342:1993;133-136.
56. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 31:1998;684-691.
57. McFadden E.P., Clarke J.G., Davies G.J., Kaski J.C., Haider A.W., Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 324:1991;648-654.
58. Zeiher A.M., Schachinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 92:1995;1094-1100.
59. Luscher T.F., Wenzel R.R., Noll G. Local regulation of the coronary circulation in health and disease role of nitric oxide and endothelin . Eur Heart J. 16:(Suppl C):1995;51-58.
60. Moncada S., Herman A.G., Higgs E.A., Vane J.R. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 11:1977;323-344.
61. Farb A., Burke A.P., Tang A.L., et al. Coronary plague erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
62. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686.